Highest-materiality recent filing
Nasdaq notified HeartSciences on Aug 4, 2026 of non-compliance with Rule 5550(b)(1) requiring $2.5M stockholders' equity.
HeartSciences files proxy for Fortitude Mining all-stock merger; FY2026 cash $1.7M, no revenue
Filed preliminary proxy for all-stock merger with Fortitude Mining; ~107.6M shares to DCG, pro forma equity $70M.
HeartSciences files 8-K/A with Fortitude Mining financials for pending merger
Amendment provides audited Fortitude financials for years ended Dec 31, 2025 (revenue $89.5M, net loss $12.7M) and 2024 (revenue $81.8M, net loss $14.4M).
HeartSciences Amends Merger Agreement with Fortitude Mining Holdings
Amendment No. 1 to Merger Agreement dated July 27, 2026, among HeartSciences, Fortitude Mining Holdings, Fortitude Mining HoldCo, and Cordis Acquisition.
HeartSciences files FY2026 10-K; expects to file proxy for Fortitude merger shortly
Filed Annual Report on Form 10-K for fiscal year ended April 30, 2026.
HeartSciences enters merger agreement with Fortitude Mining and amends CFO terms
HeartSciences entered a Merger Agreement with Fortitude Mining Holdings on June 23, 2026, to acquire Fortitude Mining HoldCo.
HeartSciences signs merger with Fortitude Mining; new CEO and CFO named
Agreement and Plan of Merger with Fortitude Mining Holdings, Fortitude Mining HoldCo and Cordis Acquisition; closing subject to conditions.
HeartSciences enters all-stock merger agreement with Fortitude Mining; combined co to trade as TUDE
Definitive all-stock merger: HeartSciences to combine with Fortitude Mining Holdings; combined entity to operate as Fortitude.
HeartSciences to acquire Fortitude Mining; Fortitude holders to own ~95% of combined entity
Merger with Fortitude Mining (Zcash mining, owned by Digital Currency Group) signed; closing expected H2 2026.
HeartSciences annual meeting approves director, stock plan, auditor; officer exculpation fails
Andrew Simpson re-elected Class III director with 577,840 for, 107,738 withheld, 1,288,285 broker non-votes.
HeartSciences COO and Board Member Mark Hilz passes away at 67
Mark Hilz, COO, Corporate Secretary and Board member, died April 1, 2026 after an illness.
HeartSciences reports no FQ3 2026 revenue, cash at $3.4M; MyoVista platform advances
No revenue for FQ3 2026; cash and equivalents $3.4M, shareholders' equity $2.7M as of Jan 31.
HeartSciences issues $3.6M 12% promissory note to Streeterville Capital, netting $3M
Company entered Note Purchase Agreement with Streeterville Capital for $3,605,000 promissory note, netting $3,000,000 after $600,000 OID and $5,000 expenses.
HeartSciences adopts standard indemnification agreements for directors and officers
Board approved form of Indemnification Agreement for all directors and executive officers on December 15, 2025.
HeartSciences reports no Q2 revenue, $2M cash; submits wavECG to FDA
No meaningful revenue for FQ2 2026; cash and equivalents $2.0M, shareholders' equity $4.2M as of Oct 31, 2025.
Board approved Amendment No. 3 to 2023 Equity Incentive Plan, increasing authorized shares from 1M to 1.25M plus annual evergreen.
HeartSciences extends loan maturity to 2026, raises $6.7M in Reg A, exchanges $2.06M debt for equity
Loan maturity extended to Sept 30, 2026; accrued interest payment structure amended.
HeartSciences regains Nasdaq minimum equity compliance; delisting risk cleared
Received formal notice on Sept 16, 2025 that it regained compliance with Nasdaq Listing Rule 5550(b)(1) requiring minimum $2.5M stockholders' equity.
HeartSciences reports Q1 FY2026 with $2.8M cash; launches MyoVista Insights platform
No meaningful revenue for Q1 FY2026; cash and equivalents $2.8M, shareholders' equity $3.1M as of July 31, 2025.
HeartSciences raises $5.4M in Reg A offering, exchanges $1.8M debt for shares
Received $5.4M gross proceeds from Reg A offering of units at $3.50; 1,556,409 units issued as of Sep 5, 2025.
HeartSciences raises $5.2M in Reg A offering and exchanges $1.655M debt for equity
Gross proceeds of $5.2M from offering of 1,484,440 Units at $3.50/Unit as of Aug 22, 2025.
HeartSciences increases ATM equity offering limit to $25M in amended distribution agreement
Amendment No. 3 to Equity Distribution Agreement raises maximum offering from $15M to $25M of common stock.
HeartSciences raises $4.3M in Reg A offering; exchanges $1.1M debt for equity
Gross proceeds of $4.3M from 1,241,188 units at $3.50/unit in Regulation A offering.
HeartSciences reports no FY2025 revenue, $1.1M cash; advances MyoVista platform
Zero revenue for fiscal year ended April 30, 2025; cash and equivalents $1.1M, shareholders' equity $0.2M.
HeartSciences updates Regulation A offering: $2.8M raised, 797K units issued, 486K shares converted
Gross proceeds of $2.8M from 797,452 Units at $3.50/unit, each consisting of Series D Preferred and a warrant.
HeartSciences expands equity plan to 1M shares, grants RSUs and options tied to FDA clearance
Board approved amendment to 2023 Equity Incentive Plan increasing maximum shares to 1,000,000; subject to shareholder vote at next annual meeting.
HeartSciences amends bylaws to add jury waiver, 3% derivative threshold
Adds jury trial waiver for 'internal entity claims' under Texas Business Organizations Code.
HeartSciences launches $15M offering of Series D Preferred and warrants
Placement Agent Agreement with Digital Offering LLC for best-efforts offering of up to 4,285,714 Units at $3.50 each.
FDA granted Breakthrough Device designation for HeartSciences' Aortic Stenosis AI-ECG algorithm.
HeartSciences granted foundational US patent for ECG-based heart function assessment
USPTO granted patent covering estimation of heart function measures via ECG; critical for early detection of heart disease.
HeartSciences files Certificate of Designations for Series D Preferred Stock in $15M offering
Designates 4,285,714 shares of Series D Convertible Preferred Stock for the Unit offering (each Unit: one Series D share + warrant to buy common at $5.00).
Nasdaq grants HeartSciences extension to Sept 15, 2025 for equity rule; Q3 cash $2.6M, equity $1.8M
Nasdaq extension to Sept 15, 2025 to regain $2.5M minimum stockholders' equity; delisting if not met by Oct 31, 2025 10-Q filing.
HeartSciences receives Nasdaq delisting notice over $1.79M equity vs $2.5M minimum
Received Nasdaq deficiency letter on March 19, 2025: stockholders' equity of $1.79M below $2.5M minimum.
HeartSciences Q3 FY2025 no revenue, cash $2.6M; FDA submission for MyoVista device expected H1 2025
No revenue for Q3 FY2025; cash and equivalents $2.6M, shareholders' equity $1.8M as of Jan 31, 2025.
HeartSciences grants 117K options to execs and directors at $3.33 strike
CEO Andrew Simpson and COO Mark Hilz each receive 45,000 options; CFO Danielle Watson receives 9,000.
HeartSciences withdraws S-1 registration statement for proposed public offering
Withdrew Registration Statement on Form S-1 filed June 7, 2023 (as amended).
No revenue in Q2 FY2025; cash and equivalents $4.1M, shareholders' equity ~$4.0M at Oct 31, 2024.
HeartSciences stockholders ratify auditor and approve adjournment at annual meeting
Ratified Haskell & White LLP as auditor for FY2025: 413,499 for, 9,896 against, 1,116 abstain.
Heart Test Laboratories officially changes name to HeartSciences Inc.; Nasdaq trading starts Oct 23
Name change from Heart Test Laboratories, Inc. to HeartSciences Inc. effective Oct 11, 2024, confirmed by Texas Secretary of State.
Filed Certificate of Amendment with Texas on October 11, 2024 to change name to HeartSciences Inc.
Cash and cash equivalents of $4.3M as of July 31, 2024; shareholders' equity of $5.9M.
Issued $2.51M unsecured promissory note to Streeterville Capital; 8.5% interest, 18-month maturity, $500K OID.
Heart Test Labs extends $500k loan maturity to Sep 2025; accelerates interest payments
Principal $500,000 at 12% compounded annually; maturity extended from Sep 30, 2024 to Sep 30, 2025.
HeartSciences reports FY2024 cash of $5.8M; cloud-platform beta and FDA timeline updates
Cash and equivalents $5.8M; shareholders' equity $7.3M as of April 30, 2024.
HeartSciences regains Nasdaq minimum bid price compliance; hearing cancelled
Nasdaq notified HeartSciences on June 3, 2024 that it regained compliance with $1.00 minimum bid price requirement.
Heart Test Labs obtains temporary stay of Nasdaq delisting; hearing set for June 27
Nasdaq delisting action stayed pending oral hearing on June 27, 2024.
Heart Test Laboratories files 8-K/A to clarify reverse stock split and warrant adjustments
Heart Test Laboratories filed Amendment No. 1 to Form 8-K to clarify details of its 1-for-100 reverse stock split.
Heart Test Laboratories to effect 1-for-100 reverse stock split on May 17, 2024
Reverse stock split of common stock and warrants at 1-for-100 ratio, effective at market open on May 17, 2024.
Received Nasdaq staff determination to delist under Low Priced Stocks Rule (closing bid ≤$0.10 for 10 consecutive days).
HeartSciences Q3 cash $7.1M; licenses AI-ECG from Mount Sinai; FDA 510(k) path
No significant revenue in Q3 FY2024; cash $7.1M, shareholders' equity $8.6M as of Jan 31, 2024.
Effective December 27, 2022, Patrick Kanouff voluntarily resigned from the Board of Directors (the “Board”) of Heart Test Laboratories, Inc. (the “Company”).
Effective December 28, 2022, the Board appointed David R. Wells to the Board as a director to fill the vacancy created by Mr. Kanouff’s resignation.
Max materiality 0.95 · Median 0.60 · Most common event other_material